Objective To explore the clinical efficacy and safety of breast conserving surgery combined with epirubicin neoadjuvant chemotherapy for breast cancer.Methods 60 patients with breast cancer were selected;based on the agreements,the patients were randomly divided into the control group and the observation group,30 cases in each.The observation group adopted the breast conserving surgery under the endoscope and the control group adopted the conventional breast conserving surgery.Be-fore treatment,the 2 groups adopted TE chemotherapy regimen.Results In the observation group,there were 28 survivors and 3 recurrent cases;3-year survival rateand 3-year recurrence rate were 93.3%and 10.0%;in the control group,there were 27 survi-vors and 4 recurrent cases;3-year survival rate and 3-year recurrence rate of control group were 90.0%and 13.3%(P>0.05);the average operation time of the observation group and the control group were(85.72 ±12.56)min and(81.29 ±11.16)min(P>0.05);during surgery,the average eliminating number of lymph nodes of the observation group and the control group were (15.32 ±1.58) and(14.87 ±1.93) ( P>0.05);the average time of drainage and extubation of the observation group were (321.98 ±28.62)ml and(4.81 ±1.52)d while those of the control group were(534.62 ±31.82) ml and(8.10 ±2.14) d(P<0.05).In terms of the postoperative beauty of breast,the observation group was better than that of the control group(P<0.05). The adverse reactions were mainly in stageⅠ~Ⅱ.Upon the expectant treatment,the symptoms were automatically disappeared after chemotherapy.Conclusion The breast conserving surgery combined with epirubicin neoadjuvant chemotherapy for breast cancer is effective,can maintain the beauty of breast and have fewer adverse reactions.It can be primary treatment for early breast cancer.%目的：探讨乳腺癌保乳术结合表柔比星新辅助化疗在乳腺癌治疗中的临床疗效，并对其安全性作出评价。方法选取2007年1月至2012年5月间收治的60例乳腺癌患者为研究对象。在患者知情同意的情况下将其随机分为对照组与观察组，各30例。观察组行保乳术结合表柔比星新辅助化疗进行治疗，对照组行乳腺癌根治术治疗。结果观察组3年生存28例，复发3例，3年生存与复发率分别为93．3％、10．0％；对照组3年生存27例、复发4例，3年生存与复发率分别为90．0％与13．3％，2组间3年生存率与复发率无统计学差异（ P＞0．05）。观察组手术时间平均为（85．72±12．56）min，对照组为（81．29±11．16）min，差异无统计学意义（P＞0．05）；观察组术中清扫淋巴结数平均为（15．32±1．58）枚，对照组为（14．87±1．93）枚，差异无统计学意义（P＞0．05）；观察组的术中平均引流量与拔管时间分别为（321．98±28．62）ml、（4．81±1．52）d，对照组为（534．62±31．82）ml、（8．10±2．14）d，组间比较观察组患者的平均引流量与拔管时间均较对照组显著缩短（P＜0．05）。乳房美容效果观察组明显优于对照组（P＜0．05）。全组患者的不良反应多为Ⅰ～Ⅱ，均给予相关对症处理，在化疗停止后自行消失。结论乳腺癌保乳术结合表柔比星新辅助化疗治疗乳腺癌，临床疗效理想，可获得更好的乳房外观效果，同时药物不良反应可耐受，可作为早期乳腺癌治疗的首选手术方法。
展开▼
